QualityStocks would like to highlight SANUWAVE Health Inc. (OTCBB: SNWV). SANUWAVE Health is an emerging regenerative medicine company focused on the development and commercialization of noninvasive, biological response activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. The company’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration.
In the company’s news yesterday, SANUWAVE Health Inc. announced that positive data from its phase III clinical trial of dermaPACE® for the treatment of diabetic foot ulcers was the subject of a Continuing Medical Education (CME) accredited presentation at Desert Foot 2011: The 8th Annual High Risk Diabetic Foot Conference, honoring Federal Service Healthcare Providers, in Phoenix, Ariz.
The company’s PACE® technology delivers high-energy acoustic pressure waves to accelerate inflammatory response to speed up the body’s natural healing process.
Robert Frykberg, DPM, MPH, chairman of Desert Foot 2011, a surgeon at the Carl T. Hayden Veterans Affairs Medical Center in Phoenix, and a principal investigator in the dermaPACE clinical trial, presented the technology in an exhibition titled “A Shocking RCT: Getting Wounds to Heal.”
Dr. Frykberg’s presentation highlighted the dermaPACE pivotal phase III clinical trial results, which demonstrated statistical significance of 100% wound disclosure compared to alternative treatment, Sham-control. dermaPACE also significantly reduced the size of the target ulcer compared with Sham-control treatment, was associated with low ulcer recurrence, and was well tolerated.
“The results of this rigorously designed and executed pivotal phase III clinical trial strongly suggests dermaPACE has an effect in the stabilization, size reduction and with time complete closure of diabetic foot ulcers. Pending FDA approval, the availability and utilization of dermaPACE has the potential to positively impact the way we treat diabetic foot ulcers, and may bring us closer to our goal of improving wound outcomes through primarily cost-effective, clinically efficient pathways,” Dr. Frykberg stated in the press release.
Christopher M. Cashman, president and CEO of SANUWAVE, noted the significance of the presentation itself.
“This CME-accredited presentation to a largely federal healthcare provider audience appropriately highlights the clinical relevance of the dermaPACE study results to this clinical community. Dr. Frykberg is a leading authority in the diabetic foot ulcer field, and as a principal investigator in the dermaPACE clinical trial, he was able to speak with first-hand experience about the study results and also share his personal insights into the overall value proposition that dermaPACE may offer,” he stated.
About QualityStocks:
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
